42971-27-7Relevant academic research and scientific papers
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY
-
Paragraph 00249, (2021/04/10)
The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound
New halogenated tris-(phenylalkyl)amines as h5-HT2Breceptor ligands
Kapadia, Nirav,Ahmed, Shahrear,Harding, Wayne W.
supporting information, p. 3216 - 3219 (2016/07/12)
A series of compounds in which various halogen substituents were incorporated into a phenyl ring of a tris-(phenylalkyl)amine scaffold, was synthesized and evaluated for affinity to h5-HT2receptors. In general, all compounds were found to have
Identification of tris-(phenylalkyl)amines as new selective h5-HT2B receptor antagonists
Ponnala, Shashikanth,Kapadia, Nirav,Harding, Wayne Wesley
supporting information, p. 601 - 605 (2015/04/27)
A series of tris-(phenylalkyl)amines was synthesized and evaluated for affinity to human 5-HT2 receptors. In general, the compounds displayed high affinity (4 of 11 analogs had Ki values 2B receptor vs. other 5-HT2 receptors. Functional assays revealed that the compounds are 5-HT2B antagonists. This journal is
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine
LeGendre, Onica,Pecic, Stevan,Chaudhary, Sandeep,Zimmerman, Sarah M.,Fantegrossi, William E.,Harding, Wayne W.
scheme or table, p. 628 - 631 (2010/06/19)
The naturally occurring aporphine alkaloid nantenine, has been shown to antagonize behavioral and physiological effects of MDMA in mice. We have synthesized (±)-nantenine via an oxidative cyclization reaction with PIFA and evaluated its binding profile against a panel of CNS targets. To begin to understand the importance of the chiral center of nantenine with regards to its capacity to antagonize the effects of MDMA in vivo, (R)- and (S)-nantenine were prepared and evaluated in a food-reinforced operant task in rats. Pretreatment with either nantenine enantiomer (0.3 mg/kg ip) completely blocked the behavioral suppression induced upon administration of 3.0 mg/kg MDMA. (±)-Nantenine displayed high affinity and selectivity for the α1A adrenergic receptor among several other receptors suggesting that this α1 subtype may be significantly involved in the anti-MDMA effects of the enantiomers.
CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS
-
Page/Page column 88, (2010/07/09)
The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.
COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
-
Page/Page column 39, (2009/03/07)
Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and activate AMP-activated protein kinase. Specific stereoisomers of Corydalis compounds with lipid lowering activity include 14R-(+)-corypalmine, 14R,13S-(+)-corydaline, 14R-(+)-tetrahydropalmatin, (+)-corlumidin, d-(+)-bicuculline, and (+)-egenine.
